中生复诺健

Sinopharm CNBG-Virogin Biotech is a joint venture between China National Biotec Group (CNBG) and Virogin Biotech, specializing in the development of next-generation oncolytic viruses and mRNA vaccines. The company utilizes the proprietary Synerlytic platform to engineer oncolytic herpes simplex virus type 1 (oHSV-1) candidates that express multiple therapeutic payloads, such as cytokines and checkpoint inhibitors, to stimulate systemic anti-tumor immunity. Its lead oncology candidate, VG161, has received Breakthrough Therapy Designation in China for advanced hepatocellular carcinoma and is currently in Phase 2 clinical trials. Additionally, the company has established a robust mRNA technology platform, leading to the development of a clinical-stage mRNA vaccine for COVID-19 and a large-scale manufacturing facility in Shanghai. The firm aims to integrate cutting-edge viral and nucleic acid technologies to address unmet needs in oncology and infectious diseases.